Public Employees Retirement Association of Colorado Raises Position in Juno Therapeutics, Inc. (JUNO)
Public Employees Retirement Association of Colorado increased its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 0.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,810 shares of the biopharmaceutical company’s stock after buying an additional 11 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Juno Therapeutics were worth $323,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the stock. Great West Life Assurance Co. Can increased its stake in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares during the period. Nisa Investment Advisors LLC bought a new stake in Juno Therapeutics during the first quarter valued at $200,000. M&T Bank Corp bought a new stake in Juno Therapeutics during the first quarter valued at $381,000. Laurion Capital Management LP bought a new stake in Juno Therapeutics during the first quarter valued at $390,000. Finally, Fairfield Bush & CO. increased its stake in Juno Therapeutics by 85.5% in the first quarter. Fairfield Bush & CO. now owns 21,475 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 9,900 shares during the period. Hedge funds and other institutional investors own 70.76% of the company’s stock.
Juno Therapeutics, Inc. (JUNO) opened at 43.81 on Wednesday. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $44.60. The firm has a 50 day moving average of $28.62 and a 200 day moving average of $25.14. The firm’s market cap is $4.60 billion.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. Juno Therapeutics’s quarterly revenue was down 22.8% compared to the same quarter last year. On average, equities research analysts expect that Juno Therapeutics, Inc. will post ($3.13) EPS for the current year.
JUNO has been the subject of several research reports. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a report on Tuesday, May 23rd. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Zacks Investment Research upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Tuesday, July 11th. Morgan Stanley dropped their target price on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Monday, May 8th. Finally, FBR & Co reiterated a “hold” rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $31.86.
In related news, Director Anthony B. Evnin bought 9,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The shares were acquired at an average price of $24.40 per share, with a total value of $219,600.00. Following the completion of the transaction, the director now owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard Klausner sold 12,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the transaction, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold 8,053,500 shares of company stock worth $217,594,440 in the last ninety days. 15.26% of the stock is currently owned by insiders.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.